· CEPI to invest up to $25.9 million, with support from the EU, in trials in East Africa to assess a vaccine candidate against...

LARISSA consortium reaches milestone Novel Rift Valley fever vaccine dosed in Phase I human trial The first healthy volunteer was dosed...

Per 31 Aug 2021 Jeroen Kortekaas resigned as CSO of BunyaVax. He has been CSO since September 2017. Jeroen will continue his career as...

Please find here our latest paper on the safety and efficacy of our veterinary Rift Valley fever vaccine: https://www.ncbi.nlm.nih.gov/pm...